FIELD: medicine.
SUBSTANCE: present invention relates to a co-crystal of a compound of lithium benzoate and a co-component, which is a co-crystal of lithium benzoate and trans-cinnamic acid in a molar ratio of 1:1, wherein the co-crystal has a pattern of powder X-ray diffraction with peaks (2Θ) in: 5.2; 7.1; 7.5; 8.0; 10.2; 12.8; 13.9; 14.5; 16.2; 17.2; 17.6; 18.5; 20.7; 21.2; 22.1; 23.0; 23.8; 24.7; 25.4; 25.8; 26.6; 27.2; 27.8; 29.1; 30.1; 30.9; 31.3; 33.6. The invention also relates to methods for obtaining co-crystals and their applications in the treatment and/or reduction in the risk of neuropsychiatric disorders (for example, schizophrenia, psychotic disorders, depressive disorders, bipolar disorders or neurodegenerative disorders).
EFFECT: obtaining co-crystals of lithium benzoate for the treatment of neuropsychiatric disorders.
5 cl, 13 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SODIUM BENZOATE COCRYSTALS AND THEIR USE | 2017 |
|
RU2771810C2 |
| D-AMINO ACID OXIDASE INHIBITORS AND THEIR THERAPEUTIC USE | 2018 |
|
RU2795513C2 |
| CYANOTHIENOTRIAZOLODIAZEPINES AND METHODS FOR THEIR USE | 2016 |
|
RU2750164C2 |
| BIVALENT BROMODOMAIN INHIBITORS AND ROUTES OF USE THEREOF | 2016 |
|
RU2742035C2 |
| NEUROACTIVE STEROIDS SUBSTITUTED AT POSITION 10 WITH A CYCLIC GROUP FOR USE IN THE TREATMENT OF CNS DISORDERS | 2019 |
|
RU2796006C2 |
| COMPOSITIONS CONTAINING BENZOATE COMPOUND AND TANNIC ACID FOR TREATMENT OF DISORDER OF CENTRAL NERVOUS SYSTEM | 2017 |
|
RU2756812C2 |
| OXYSTEROLES AND METHODS OF USING THEM | 2016 |
|
RU2742333C2 |
| NEUROACTIVE COMPOUNDS AND THEIR APPLICATION METHODS | 2015 |
|
RU2764702C2 |
| COMPOSITIONS AND METHODS FOR TOPICAL PROSTAGLANDINS DELIVERY TO SUBCUTANEOUS FAT | 2014 |
|
RU2635864C2 |
| THERAPEUTIC COMPOUNDS AND COMPOSITIONS | 2015 |
|
RU2733405C2 |
